Differing spectrum of HIV-associated ophthalmic disease among patients starting antiretroviral therapy in India and South Africa
2011

HIV-Associated Eye Disease in India and South Africa

Sample size: 306 publication Evidence: moderate

Author Information

Author(s): Pathai Sophia, Gilbert Clare, Weiss Helen A, McNally Matthew, Lawn Stephen D

Primary Institution: London School of Hygiene and Tropical Medicine

Hypothesis

The prevalence and spectrum of HIV-associated ophthalmic disease differ between patients starting antiretroviral therapy in India and South Africa.

Conclusion

The study found a higher prevalence of HIV-associated ophthalmic disease in the Indian population compared to the South African population, primarily due to retinal opportunistic infections.

Supporting Evidence

  • The prevalence of HIV-associated ophthalmic disease was 17.5% in India compared to 12.1% in South Africa.
  • Retinal opportunistic infections were significantly more common in the Indian cohort.
  • Adjusted odds ratio for geographical location as a predictor of retinal disease was 11.32.

Takeaway

This study shows that people with HIV in India are more likely to have eye problems than those in South Africa, especially certain infections that can affect vision.

Methodology

The study compared two cohorts of patients starting antiretroviral therapy in Mumbai, India, and Cape Town, South Africa, using demographic data, ocular symptom screening, and ophthalmic examinations.

Potential Biases

Potential biases may arise from differences in healthcare access and treatment protocols between the two locations.

Limitations

The study may not account for all confounding factors affecting the prevalence of eye disease, and the populations studied may not be fully representative of all HIV-infected individuals in these regions.

Participant Demographics

Patients were similar in demographic and clinical characteristics, with a lower median CD4 count in the Cape Town cohort.

Statistical Information

P-Value

0.003

Confidence Interval

95% CI: 2.67–48.13

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1111/j.1365-3156.2010.02712.x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication